26Traditional antibiotics are reaching obsolescence as a consequence of antibiotic 27 resistance; therefore novel antibiotic approaches are needed. A recent non-traditional approach 28 involves formation of protein aggregates as antimicrobials to disrupt bacterial homeostasis. 29 Previous work on protein aggregates has focused on genome mining for aggregation-prone 30 sequences in bacterial genomes rather than on rational design of aggregating antimicrobial 31 peptides. Here, we use a synthetic biology approach to design an artificial gene encoding the first 32 de novo aggregating antimicrobial peptide. This artificial gene, opaL (overexpressed protein 33 aggregator Lipophilic), disrupts bacterial homeostasis by expressing extremely hydrophobic 34 peptides. When this hydrophobic sequence is disrupted by acidic residues, consequent 35 aggregation and antimicrobial effect decreases. Further, to deliver this artificial gene, we 36 developed a probiotic approach using RK2, a broad host range conjugative plasmid, to transfer 37 opaL from donor to recipient bacteria. We utilize RK2 to mobilize a shuttle plasmid carrying the 38 opaL gene by adding the RK2 origin of transfer. We show that opaL is non-toxic to the donor, 39 allowing for maintenance and transfer since its expression is under control of a promoter with a 40 recipient-specific T7 RNA polymerase. Upon mating of donor and recipient Escherichia coli, we 41 observe selective growth repression in T7 polymerase expressing recipients. This technique 42 could be used to target desired pathogens by selecting pathogen-specific promoters to control 43 opaL expression. This system provides a basis for the design and delivery of novel antimicrobial 44 peptides. 45 46 47 3 48 Importance 49The growing threat of antibiotic resistance necessitates new treatment options for 50 bacterial infections that are recalcitrant to traditional antimicrobials. Existing methods usually 51 involve small-molecule compounds which interfere with essential processes in bacterial cells. By 52 contrast, protein aggregates operate by causing widespread disruption of bacterial homeostasis 53 and may provide a new method for combating infections. We used rational design to create and 54 test an aggregating de novo antimicrobial peptide, OpaL. In addition, we employed bacterial 55 conjugation to deliver the opaL gene from donor bacteria to recipient bacteria while using a 56 strain-specific promoter to ensure that OpaL was only expressed in targeted recipients. To the 57 best of our knowledge, this represents the first design for a de novo peptide with aggregation-58 mediated antimicrobial activity. We envision that OpaL's design parameters could be used in 59 developing a new class of antimicrobial peptides to help treat antibiotic resistant infections. 60 61 1 Introduction 62 Traditional antibiotic treatments are losing efficacy as bacteria gain resistance to 63 available antimicrobial compounds. This resistance arises through a variety of mechanisms such 64 as altered target sites, excl...